Arielle Janine Medford, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 15 | 2024 | 21156 | 0.710 |
Why?
|
Immunoconjugates | 2 | 2022 | 968 | 0.560 |
Why?
|
Neoplasms | 4 | 2024 | 22386 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9425 | 0.380 |
Why?
|
Breast | 1 | 2018 | 1976 | 0.310 |
Why?
|
Estrogen Receptor alpha | 3 | 2024 | 582 | 0.300 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6091 | 0.300 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2024 | 564 | 0.210 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1014 | 0.190 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2024 | 352 | 0.180 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2024 | 958 | 0.180 |
Why?
|
Receptor, erbB-3 | 1 | 2021 | 142 | 0.180 |
Why?
|
Acidosis, Lactic | 1 | 2021 | 146 | 0.170 |
Why?
|
Vulnerable Populations | 1 | 2024 | 717 | 0.160 |
Why?
|
Carcinoma, Lobular | 1 | 2022 | 480 | 0.150 |
Why?
|
Camptothecin | 1 | 2021 | 594 | 0.150 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8051 | 0.140 |
Why?
|
Prognosis | 4 | 2024 | 30028 | 0.130 |
Why?
|
Serine | 1 | 2019 | 831 | 0.130 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2022 | 1092 | 0.120 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4931 | 0.120 |
Why?
|
Ki-67 Antigen | 1 | 2016 | 631 | 0.110 |
Why?
|
Metformin | 1 | 2021 | 914 | 0.110 |
Why?
|
Specimen Handling | 1 | 2018 | 709 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5342 | 0.100 |
Why?
|
Mutation | 5 | 2024 | 30243 | 0.100 |
Why?
|
Humans | 22 | 2024 | 768451 | 0.100 |
Why?
|
Female | 17 | 2024 | 396943 | 0.090 |
Why?
|
Phosphoproteins | 1 | 2019 | 2450 | 0.090 |
Why?
|
Aromatase Inhibitors | 2 | 2024 | 518 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1749 | 0.090 |
Why?
|
Proteome | 1 | 2019 | 1881 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 906 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1943 | 0.080 |
Why?
|
Genotype | 1 | 2023 | 13047 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 3111 | 0.080 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2009 | 302 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 3611 | 0.070 |
Why?
|
Platelet Transfusion | 1 | 2009 | 301 | 0.070 |
Why?
|
Telemedicine | 1 | 2023 | 3104 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2544 | 0.060 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2024 | 131 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2884 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11249 | 0.050 |
Why?
|
Receptor, erbB-2 | 2 | 2023 | 2586 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2024 | 13708 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 2009 | 2702 | 0.050 |
Why?
|
Phosphoglycerate Dehydrogenase | 1 | 2019 | 38 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4362 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 682 | 0.040 |
Why?
|
Graft Rejection | 1 | 2009 | 4505 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4041 | 0.030 |
Why?
|
Glycine | 1 | 2019 | 672 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2024 | 2243 | 0.030 |
Why?
|
Creatinine | 1 | 2021 | 1915 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1320 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2022 | 2046 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2546 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2834 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 17149 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3619 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3629 | 0.020 |
Why?
|
Minor Histocompatibility Loci | 1 | 2009 | 16 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 81834 | 0.020 |
Why?
|
Mice, Congenic | 1 | 2009 | 98 | 0.020 |
Why?
|
Aged | 4 | 2024 | 171520 | 0.020 |
Why?
|
Gene Frequency | 1 | 2015 | 3615 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2019 | 2901 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2016 | 1357 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5709 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 2009 | 234 | 0.020 |
Why?
|
Signal Transduction | 2 | 2024 | 23638 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5909 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4120 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2015 | 2594 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13026 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5367 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9263 | 0.020 |
Why?
|
Isoantibodies | 1 | 2009 | 682 | 0.020 |
Why?
|
Middle Aged | 3 | 2024 | 223418 | 0.010 |
Why?
|
Adult | 3 | 2024 | 223542 | 0.010 |
Why?
|
Animals | 3 | 2024 | 169418 | 0.010 |
Why?
|
Transplantation Conditioning | 1 | 2009 | 1598 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6551 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2009 | 4834 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2009 | 6241 | 0.010 |
Why?
|
Blood Platelets | 1 | 2009 | 2485 | 0.010 |
Why?
|
Mice | 2 | 2019 | 82045 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12242 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9558 | 0.010 |
Why?
|
Heart Failure | 1 | 2021 | 11857 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 22365 | 0.010 |
Why?
|